CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CRSP · as of Sep 30, 2025
Ownership Breakdown
488
Institutional Holders
▲ 9 vs Q2
$4.68B
Total Inst. Value
▲ $1.16B vs Q2
96.45M
Shares Outstanding
freeFloat 99.56%
72.25M
13F Shares Held
▼ 264,492 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CRSP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ARK INVESTMENT MANAGEMENT LLC biological products, (no diagnostic substances) | 9.79M | 11.24% | 11.24% | $634.29B | Nov 12, 2025 | ▼ 395.6K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.05M | 8.10% | 8.10% | $456.92B | Nov 12, 2025 | ▲ 983.8K |
CAPITAL INTERNATIONAL INVESTORS biological products, (no diagnostic substances) | 5.65M | 6.49% | 6.49% | $366.13B | Nov 13, 2025 | ▲ 55.5K |
ORBIS ALLAN GRAY LTD biological products, (no diagnostic substances) | 4.98M | 5.72% | 5.72% | $322.89B | Nov 14, 2025 | ▲ 2.22M |
STATE STREET CORP biological products, (no diagnostic substances) | 4.01M | 4.60% | 4.60% | $259.71B | Nov 14, 2025 | ▲ 736.6K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 3.28M | 3.77% | 3.77% | $212.75B | Nov 14, 2025 | ▼ 400.4K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.36M | 2.72% | 2.72% | $153.25B | Nov 7, 2025 | ▲ 66.6K |
UBS GROUP AG biological products, (no diagnostic substances) | 2.34M | 2.69% | 2.69% | $151.59B | Nov 13, 2025 | ▼ 504.5K |
SUMITOMO MITSUI TRUST HOLDINGS, INC. biological products, (no diagnostic substances) | 2.16M | 2.48% | 2.48% | $140.23B | Oct 27, 2025 | ▼ 251.2K |
NIKKO ASSET MANAGEMENT AMERICAS, INC. biological products, (no diagnostic substances) | 2.16M | 2.48% | 2.48% | $140.18B | Nov 12, 2025 | ▼ 250.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
25
Increased
+8.21M shares1
New Positions
first time holders22
Decreased
−5.24M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.97M
+8.21M / −5.24M
Net new holders
+4
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CRSP insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
23
Buy transactions
35
Sell transactions
0.66
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
KASINGER JAMES R. General Counsel and Secretary | May 29, 2026 | Award | 17,000 | — | — | 17.0K | Form 4 ↗ |
Patel Naimish Chief Medical Officer | May 29, 2026 | Award | 22,000 | — | — | 22.0K | Form 4 ↗ |
Prasad Raju Chief Financial Officer | May 29, 2026 | Award | 19,500 | — | — | 19.5K | Form 4 ↗ |
Patel Naimish Chief Medical Officer | May 29, 2026 | Sale | 3,786 | $55.62 | $210.6K | 19.4K | Form 4 ↗ |
KASINGER JAMES R. General Counsel and Secretary | Mar 23, 2026 | Sale | 3,182 | $46.78 | $148.9K | 94.3K | Form 4 ↗ |
KASINGER JAMES R. General Counsel and Secretary | Mar 20, 2026 | Award | 38,499 | $46.24 | $1.78M | 38.5K | Form 4 ↗ |
KASINGER JAMES R. General Counsel and Secretary | Mar 20, 2026 | Award | 25,000 | — | — | 25.0K | Form 4 ↗ |
Kulkarni Samarth Chief Executive Officer | Mar 23, 2026 | Sale | 10,020 | $46.78 | $468.7K | 255.5K | Form 4 ↗ |
Kulkarni Samarth Chief Executive Officer | Mar 20, 2026 | Award | 114,249 | $46.24 | $5.28M | 114.2K | Form 4 ↗ |
Kulkarni Samarth Chief Executive Officer | Mar 20, 2026 | Award | 81,875 | — | — | 81.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
CRISPR Therapeutics AG (CRSP) is primarily owned by institutional investors, who hold approximately 74.9% of total shares outstanding. Company insiders own approximately 0.44%, while retail and public investors account for the remaining 24.66%.
The largest institutional shareholder of CRISPR Therapeutics AG is ARK INVESTMENT MANAGEMENT LLC, holding approximately 9.79 million shares — equal to 11.24% of outstanding shares — as of September 30, 2025.
A total of 488 institutional investors currently hold CRSP stock, with a combined institutional value of approximately $4.68 billion as of the most recent 13F filing period.
Frequently asked questions
CRSP ownershipCRISPR Therapeutics AG (CRSP) is primarily owned by institutional investors, who hold approximately 74.9% of shares. The largest shareholder is ARK INVESTMENT MANAGEMENT LLC with a 11.24% stake. Company insiders hold 0.44%. Data sourced from SEC Form 13F as of September 30, 2025.